January 2008

All Things Considered, the Answer Is a Resounding Yes

ByGordon K. Norman, MD, MBA. Author reply by Soeren Mattke, MD, DSc,Michael Seid, PhD,Sai Ma, PhD

January 15th 2008

Lowering LDL-C for Optimal Protection in High-risk Patients

ByFrank M. Shanley, DO. Author reply by Kenneth C. Goldberg, MD

January 15th 2008

Unrecognized Confounders in Overcoming Clinical Inertia Study

ByDaniel G. Federman, MD. Author reply by Kenneth C. Goldberg, MD

January 15th 2008

Effects of Health Education on Glycemic Control During Holiday Time in Patients with Type 2 Diabetes Mellitus

ByHarn-Shen Chen, MD, PhD,Tzu-En Wu, MD,Tjin-Shing Jap, MD,Ru-Lin Chen, BSc,Hong-Da Lin, MD

January 15th 2008

Do Diabetes Group Visits Lead to Lower Medical Care Charges?

ByDawn E. Clancy, MD, MSCR,Clara E. Dismuke, PhD,Kathryn Marley Magruder, PhD, MPH,Kit N. Simpson, DrPH,David Bradford, PhD

January 15th 2008

Among a diabetes group visit population, this study found substantial savings in outpatient charges due to reduction in the use of more expensive specialty visits.

Diabetes Diagnosis, Resource Utilization, and Health Outcomes

ByMartin C. Gulliford, FFPH,Radoslav Latinovic, BSc,Judith Charlton, MSc

January 15th 2008

Lower Severe Hypoglycemia Risk: Insulin Glargine Versus NPH Insulin in Type 2 Diabetes!

ByGeorge Dailey, MD,Poul Strange, MD

January 15th 2008

Diabetes Complications Severity Index and Risk of Mortality, Hospitalization, and Healthcare Utilization

ByBessie Ann Young, MD, MPH,Elizabeth Lin, MD, MPH,Michael Von Korff, ScD,Greg Simon, MD, MPH,Paul Ciechanowski, MD, MPH,Evette J. Ludman, PhD,Siobhan Everson-Stewart, BA,Leslie Kinder, PhD,Malia Oliver, BA,Edward J. Boyko, MD, MPH,Wayne J. Katon, MD

January 15th 2008

How Managed Care Organizations Contribute to Improved Diabetes Outcomes

ByPatricia R. Salber, MD, MBA

January 15th 2008

January 2008

All Things Considered, the Answer Is a Resounding Yes

Lowering LDL-C for Optimal Protection in High-risk Patients

Unrecognized Confounders in Overcoming Clinical Inertia Study

Effects of Health Education on Glycemic Control During Holiday Time in Patients with Type 2 Diabetes Mellitus

Do Diabetes Group Visits Lead to Lower Medical Care Charges?

Diabetes Diagnosis, Resource Utilization, and Health Outcomes

Lower Severe Hypoglycemia Risk: Insulin Glargine Versus NPH Insulin in Type 2 Diabetes!

Diabetes Complications Severity Index and Risk of Mortality, Hospitalization, and Healthcare Utilization

How Managed Care Organizations Contribute to Improved Diabetes Outcomes

Trending on AJMC

Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges

Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote

Surrogate End Points, Drug Costs Complicate Oncology Formularies

Melatonin Use Linked to Small REM Sleep Reduction in Children

FDA Approves Belzutifan-Lenvatinib Combo for Advanced Kidney Cancer

Building a Cellular Therapy Program in the Community Oncology Setting: Perspectives and Lessons Learned

January 2008

All Things Considered, the Answer Is a Resounding Yes

Lowering LDL-C for Optimal Protection in High-risk Patients

Unrecognized Confounders in Overcoming Clinical Inertia Study

Effects of Health Education on Glycemic Control During Holiday Time in Patients with Type 2 Diabetes Mellitus

Do Diabetes Group Visits Lead to Lower Medical Care Charges?

Diabetes Diagnosis, Resource Utilization, and Health Outcomes

Lower Severe Hypoglycemia Risk: Insulin Glargine Versus NPH Insulin in Type 2 Diabetes!

Diabetes Complications Severity Index and Risk of Mortality, Hospitalization, and Healthcare Utilization

How Managed Care Organizations Contribute to Improved Diabetes Outcomes

Trending on AJMC

Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges

Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote

Surrogate End Points, Drug Costs Complicate Oncology Formularies

Melatonin Use Linked to Small REM Sleep Reduction in Children

FDA Approves Belzutifan-Lenvatinib Combo for Advanced Kidney Cancer